Testing two medications together for recurrent gynecologic carcinosarcoma

This trial is testing a combination treatment for women whose gynecologic carcinosarcoma (a rare and aggressive uterine cancer) has come back after previous chemotherapy. The study combines Cabozantinib, a drug that cuts off blood supply to tumors, with Dostarlimab, an immunotherapy drug that helps your body's own immune system fight cancer. The hope is that these two medications working together will be more effective than either one alone.

Immunotherapy alone has not worked well enough for gynecologic cancers. Recent research suggests that blocking blood vessel growth might help the immune system work better, so doctors want to test whether combining these two approaches gives patients a better chance of response.